A prospective, first-in-human study investigated the safety, efficacy, pharmacokinetics and pharmacodynamics of AMG-333 in healthy volunteers

Trial Profile

A prospective, first-in-human study investigated the safety, efficacy, pharmacokinetics and pharmacodynamics of AMG-333 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs AMG 333 (Primary)
  • Indications Migraine
  • Focus First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 25 Apr 2016 New trial record
    • 12 Mar 2016 Population pharmacokinetics/pharmacodynamics and exposure-response analysis (n=40) were presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top